Castle Biosciences (CSTL) FCF Margin (2018 - 2026)

Castle Biosciences has disclosed FCF Margin across 9 years of filings, most recently posting 41.33% for Q1 2026.

• FCF Margin for Q1 2026 came in at 41.33%, down 3081.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.86% (down 734.0% YoY), and the FY2025 annual result was 18.08%, down 145.0% from the prior year.
• FCF Margin came in at 41.33% for Q1 2026 at Castle Biosciences, down from 61.66% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 61.66% in Q4 2025 to a low of 79.93% in Q1 2022.
• The 5-year median for FCF Margin is 6.65% (2023), against an average of 5.32%.
• Peak annual rise in FCF Margin reached 14306 bps in 2022, while the deepest fall reached 11677 bps in 2022.
• Castle Biosciences' FCF Margin stood at 9.26% in 2022, then soared by 342 bps to 22.37% in 2023, then jumped by 134 bps to 52.28% in 2024, then gained by 18 bps to 61.66% in 2025, then slumped by 167 bps to 41.33% in 2026.
• The last three FCF Margin figures came in at 41.33% (Q1 2026), 61.66% (Q4 2025), and 0.74% (Q3 2025), per Business Quant data.